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Abstract 
 
Background.Adenosine, an ATP derivative, may be implicated in some kinds of unexplained 
syncope. In patients with normal heart, normal ECG and recurrent sudden-onset syncope without 
prodromes have been shown to present with lowplasmatic adenosine levels and a high 
susceptibility to exogenous adenosine.The term “low-adenosine syncope” has been launched to 
describe this distinct clinical entity.  
Objectives. We decided to investigate whether chronic treatment of these patients with 
theophylline, a non-selective adenosine receptor antagonist, results in clinical benefit. 
Methods. We report on the prolonged clinical observation of 6 “low-adenosine” syncope patients 
(mean age 50±20 years, 4 females) treated with oral theophylline within the therapeutic range of 
12-18 μg/ml.  We were able to make an intrapatient comparison between a period with and a 
period without theophylline therapy.   
Results. In five patients, symptoms disappeared and the number of prolonged asystolic pauses 
detected by implantable loop recorder (ILR) fell impressively from a median of 1.11 per month 
(interquartile range 0.4 -1.8)during 13 months of no-treatment (range 2-36) to 0 per month(0-0.7) 
during 20 months of theophylline treatment (range 6-120). The 6th patient, was unresponsive to 
theophylline therapy, and a different mechanism of syncope was hypothesized. 
Conclusion. In this small series of highlyselected patients affected by syncope with low circulating 
adenosine levels, theophylline proved to be an effective therapy in most patients. The logical 
inference is that the adenosine pathway has a causal role in the mechanism of syncope in such 
patients.  
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Introduction 
 
Adenosine, an ATP derivative, may be implicated in some kinds of unexplained syncope. Patients 
with unexplained syncope of sudden onset, a normal heart and normal ECG (so-called 
“unexplained syncope, no prodromes and normal heart”)have been shown to be different from 
vasovagal syncope patients (1,2).Rather, their clinical and biological features are close to those 
observed in patients affected by idiopathic paroxysmal AV block (3).Patients with syncope without 
prodromes and normal heart and patients with idiopathic AV block have an adenosine 
profilewhich is opposite to that observed in vasovagal syncope patients and is characterized by 
very low plasmatic adenosine values, low expression of A2Aadenosine receptors and a high 
induction rate of transient complete heart block during exogenous injections of adenosine (4). 
Unlike in vasovagal syncope patients, tilt testing is usually negative (4). These forms of syncope 
have been labelled “low-adenosine syncope” (1) and this terminology will be used throughout this 
manuscript. 
 Since patients with low plasma adenosine levels are highly susceptible to exogenous and 
endogenousadenosine (2-6)  we wanted to investigate if treatment with theophylline, a non-
selective adenosine receptor antagonist, should result in prevention of syncopal recurrences. We 
found the opportunity to test this hypothesis in a highly selected subset of patients who will be 
described in this manuscript 
 
Description of patients  
 
We report on the prolonged clinical observation of 6 “low-adenosine” syncope patients (mean age 
50±20 years, 4 females) treated with oral theophylline within the therapeutic range of 12-
18μg/ml. The patients had common major clinical features: 1) a long-standing history (median 8 
years, range 3-30 years) of recurrent unexplained syncopes without prodromes, normal heart and 
normal ECG; and 2) baseline values of plasmatic adenosine (0.11±0.03 μmol/L) well below the 5th 
percentile of the value of normal subjects (0.40 μmol/L) [4]). Multiple episodes of paroxysmal AV 
block and sinus-atrial arrest were documented at the time of (pre)syncopes in 4 and 1 patients, 
respectively; in another patient, documentation of the mechanism was lacking, as no ECG 
monitoring was active at the time of symptoms.Patient characteristics are listed in Table 1.  
 We had the opportunity to perform an intrapatient comparison between a period with and 
a period without theophylline therapywith the support of prolonged ECG monitoring in the 
majority of them (Table 2).The follow-up of all patients is updated to July 2015.  
 Specifically: 
 patient #1 was seen in 1995 and followed up for 20 years. In 1995, Holter monitoring 
fortuitously recorded idiopathic paroxysmal AV block, which was reproduced on the 
adenosine triphosphate test (ATP test). For the next 10 years, she underwent theophylline 
therapy, during which time she had no syncopal recurrences. In 2005, soon after discontinuing 
theophylline, she had a syncopal recurrence, for which she received an implantable loop 
recorder (ILR); over the next 3 years, 2 further episodes of idiopathic paroxysmal AV block 
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with long asystolic pauses up to 22 s were documented. In 2008, she received a permanent 
pacemaker and has remained asymptomatic since that time. 
 patient #2 participated in a 2-period cross-over trial (Off-On-Off-On therapy) under ILR 
monitoring: episodes of idiopathic paroxysmal AV block decreased from 19 (max pause 7 s) off 
therapy to 4 (max pause 3 s) on therapy (Figure 1 and  Figure 2 panels A, B and C). 
 patient #3 had 8 syncopes in the 2 years off therapy and no recurrence during the subsequent 
2 years on therapy. Only when she started theophylline did she receive an ILR, which never 
recorded any arrhythmias. 
 in patient #4, episodes of idiopathic paroxysmal AV block dropped from 27 (max pause 7 s) off 
therapy to 0 on therapy (Figure 3). 
 patient #5 was the only patient who had a sinus-atrial arrest documented with an ILR: two 
consecutive pauses due to sinus arrest of 3 s and 6 s were preceded by few beats of slowing of 
sinus rate; he remained free of symptoms and arrhythmias during the 20 months of 
theophylline therapy. 
 we also report the case of a woman (case #6) who had very frequent (daily) pre-syncopes 
during a 3-year observation period; on several occasions, she underwent 24-hour Holter 
monitoring, which, on each occasion, detected multiple episodes of paroxysmal asystolic AV 
block preceded and followed by PR interval prolongation and 2nd degree AV block (Figure 4). 
Since the patient refused pacemaker implantation, she was treated with oral theophylline 600 
mg/day for 1.5 months: although her symptoms persisted, the episodes of asystolic AV block 
declined from 14 (longest pause 9.2 s) on pre-therapy Holter monitoring to 7 (longest 6.7 s) on 
monitoring during theophylline.  
To summarize,in 5 patients, who presented with asystole during long-term continuous ECG 
monitoring, symptoms disappeared and ECG-documented pauses were impressively reduced 
during the theophylline period in comparison with the no-treatment period.The 6th patient was 
unresponsive or hypo-responsive to theophylline therapy (Table 2). 
  
Discussion 
 
In thisseries of case reports, theophylline appearedeffective in five out of six patients with 
recurrent sudden onset (pre)syncope and who presented with the common biological 
characteristic of low circulating adenosine levels. Since theophylline is a non-selective antagonist 
of purinergic receptors, we hypothesize that purinergic receptors are involved in the mechanism 
of syncope in such patients.  
 Like other methylated xanthine derivatives, theophylline is a non-selective A1 and 
A2adenosine-receptor antagonist (10). When plasma adenosine values are far below the constant 
of dissociation (KD) value of 0.7µM for A1 adenosine receptors (A1 R) (5), as in our patients, many 
A1 R are free. A1 R are known to be located within the AV node and, to a lesser extent, in the sinus 
node, and therefore their activation may cause syncope as a result of prolonged asystolic pauses 
due to AV block or sinus arrest (2,3,4,6,11).  Theophylline is able to saturate A1 R, thus preventing 
an acute increase in plasmatic adenosine (e.g., in the case of myocardial hypoxia or during reflex 
beta-adrenergic stimulation [6,11]) from recruiting a sufficient number of receptors to cause AV 
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block or sinus-atrial arrest. In addition, as theophylline is also an almost equally potent antagonist 
of A2 receptors, which are located in the vessels and cause vasodilation, a synergic antagonist 
action of this drug may also be possible. Conversely, when baseline plasmaadenosine level is high, 
as in patients with vasovagal syncope or positive tilt testing, most high-affinity A1 R are already 
saturated, and probably desensitized; thus, adenosine release is unlikely to have an effect on A1 
receptors and consequently on heart rate (4,7). Thus, from a pathophysiological point of view, 
xanthine derivatives may probably be less effective, owing to the high dose necessary to displace 
high concentrations of adenosine from its receptors. Indeed, in an acute study (12) theophylline 
was ineffective in patients with tilt-induced vasovagal syncope whereas it was partially effective in 
preventing dipyridamole-induced syncope. 
 The above considerations could explain the variable efficacy of theophylline therapy 
reported in the literature in the absence of plasmatic adenosine assay.In 11 patients with 
recurrent unexplained syncopes and positive ATP test - which suggests an overlap with low 
adenosine patients - syncope recurred in 2 patients (15%) during a mean follow-up of 13 months 
(13). The few small observational studies existing in the literaturein patients with vasovagal 
syncope report a recurrence rate ranging between 12% and 22% (14,15,16). Finally, in a 
randomized controlled trial (17), theophylline was ineffective in preventing syncope in patients 
affected by intrinsic sick sinus syndrome compared with no treatment arm. 
Some patients in our report differ from the others. Patient #3 had undocumented syncope, 
the efficacy of theophylline could only be argued from the dramatic disappearance of symptoms 
as soon as she started the therapy.  Patient #5 presented with sinus arrest and not AV block and 
had a cardioinhibitory response with tilt test which suggests a vasovagal mechanism. On the other 
hand the clinical presentation of syncopes without prodromes (consistent with the ECG 
documentation of sudden onset sinus arrest) and low plasmatic adenosine are common features 
with the other patients and theophylline was effective. A joint involvement of both 
acetylcholinergic and purinergic pathways in this case is possible and has a solid pathophysiologial 
(6) and clinical (7,18) background in the literature. Patient #6 was not responsive to theophylline 
although she had low adenosine plasma levels; the very frequent episodes of paroxysmal AV block 
observed on each 24-hour Holter recording have features compatible with vagally-induced (8,9) 
rather than idiopathic AV block(3). However, this case was reported here since it shared the 
common biological pattern of low plasma adenosine syncope. 
 
Limitations 
The present report has several limitations, mainly due to the small number of patients 
described and the lack of a homogeneous data collection. Nevertheless, these limitations are 
partly overcome by the long follow-up – up to several years – the electrocardiographic 
documentation of syncope in most of the patients and the intrapatient control comparison.  
 The present report lacks of a formal comparison with patientswith documented episodes 
paroxysmal AV block and sinus-atrial arrest of known etiology.  We reviewed our adenosine 
database and we found 10 patients with a clinically established diagnosis of reflex syncope who 
had an ILR documentation of asystolic syncope. In contrast with the patients of the present report, 
all 9 vasovagal patients had progressive sinus bradycardia followed by sinus arrest; they had  high 
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adenosine and high expression of A2A adenosine receptors. The  patient with swallowing syncope 
had recurrent paroxysmal AV block similar to our patient #6 but  normal adenosine value (Table 3). 
Furthermore, we found 4 patients who had an intrinsic paroxysmal AV blockdue to degenerative 
disease of AV conduction system. These patients had normal adenosine values (Table 3). Thus, low 
adenosine is a typical features of patients with unexplained syncope, no prodrome and normal 
heart. We argue that in such patients theophylline has little rationale to be as effective as in our 
patients.  
 
Conclusion and perspectives 
In conclusion, theophylline seems to be able to prevent syncopal recurrences and asystolic events 
in patients with low-adenosine syncope, and may be considered as an alternative to permanent 
pacing therapy in such patients. This study provides the rationale for planning a randomized 
controlled trial aimed at confirming or refuting these results. At present it is unknown how many 
patients with unexplained syncope are actually “low adenosine” patients who could benefit of 
theophylline therapy. In the ISSUE 2 and ISSUE 3 studies(19,20), which enrolled patients with 
suspected or certain neurally-mediated syncope (prodromes were absent in about a half of them), 
an idiopathic-like paroxysmal AV block was observed in 8% of patients who had a ILR 
documentation of syncope and accounted for 22% of those of had an asystolic event. It is possible 
that some of these patients were “low adenosine” patients. 
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Figure 1.  Patient #2, affected by idiopathic paroxysmal V block. This patient participated in a 2-
period cross-over trial (Off-On-Off-On therapy) under ILR monitoring for a total of 25 months. The 
histograms show the numbers of episodes per month. Episodes of idiopathic paroxysmal AV block 
decreased from 19 (max pause 7 s) off therapy to 4 (max pause 3 s) on therapy. 
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Figure 2. Same patient as figure 1. The panels show examples of typical idiopathic paroxysmal AV 
block characterized by sudden-onset AV block without R-R cycle changes and constant PR interval. 
Panel A : Recording during the first period Off therapy: 4 consecutive P waves are blocked (pause 
of 7 s) and are followed by a conducted beat and then by another single blocked P wave. Panel B. 
Recording during the first period On therapy: the blocked P waves are reduced to 2 and the 
maximum pause is of 3 s. Panel C. Recording during the second period Off therapy. The episode 
resembles that of the first Off period:  6 consecutive P waves are blocked (pause of 6 s) and are 
followed by a conducted beat and then by another single blocked P wave. 
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Figure 3 
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Figure 3. Patient #4, affected by idiopathic paroxysmal V block. This patient participated in a cross-
over trial (Off-On therapy) under ILR monitoring for a total of 20 months. The histograms show the 
numbers of episodes per month. A total of 27 episodes of idiopathic paroxysmal AV block (max 
pause 7 s) occurred in the 13-month period off therapy; episodes disappeared completely as soon 
as the patient started theophylline therapy.   
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Figure 4 
 
 
1 s
 
 
Figure 4. Case #6. The continuous ECG tracing (lead II) shows an episode of paroxysmal AV block. 
In this patient, too, AV block occurred without P-P cycle changes; unlike case #4, however, the PR 
interval lengthens before block, from 0.20 s to 0.28 s in the beat immediately preceding the 
asystolic pause. Furthermore, the asystolic pause is followed by 2:1 AV block and then 1st degree 
AV block with prolonged PR interval up to 0.36 s in the conducted beats. PR prolongation is 
suggestive of vagal AV block (8,9) rather than adenosine AV block or idiopathic AV block (3). For 
comparison, see case 2, figure 1.  
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Table 1. Characteristics of the 6 “low-adenosine” patients who were treated with theophylline  
 
No, gender, 
age 
ECG 
documentation of 
the index event, 
(total duration/ 
longest pause) * 
Adenosine 
plasmatic level, 
μmol/L 
(normal range: 
0.40-0.78) 
A2 A adenosine 
receptor 
expression,  AU 
(normal range: 
0.40-0.80) 
Adenosine 
i.v. test, 
max pause 
Tilt table 
test 
Carotid sinus 
massage 
Electro- 
physiological 
study 
#1. F, 50 yrs 
Idiopathic AVB 
 (34/22 s) 
0.12 0.20 11 s  negative negative negative 
#2. M, 72 yrs 
Idiopathic AVB  
(11/7 s) 
0.09 0.50 neg negative negative negative 
#3. F, 20 yrs 
none (ILR only 
with theophylline) 
0.09 0.55 5.4 s negative np negative 
#4. F, 71 yrs 
Idiopathic AVB  
 (24/7 s) 
0.10 np 7 s 
positive 
mixed 
negative np 
#5. M, 41 yrs 
Sinus arrest (18/6 
s) 
0.18 0.80 7.4 s 
positive 
cardioinhib. 
negative np 
#6. F, 52 yrs 
Paroxysmal AVB  
(- /9 s) 
0.10 0.45 7.6 s negative negative negative 
 
* documentation with prolonged monitoring by means of implantable loop recorder (ILR) in cases 1,2,4 and 5 and Holter 
monitoring in case 6  
AVB = atrioventricular block; np = not performed 
Adenosine plasma level was evaluated by means of high-performance liquid chromatography, as previously described [2]. Adenosine 
A2  receptor expression was evaluated by western blot, as previously described (7). The normal ranges are between the 5
th
 and 95
th
 
percentiles of the values recorded in healthy control subjects (4). 
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Table 2. Comparative effect on outcome in 5 patients who responded to theophylline  and the one who did not 
 
Pt no,  
 
History of syncope 
before   diagnosis 
Observation without therapy Observation during theophylline therapy 
Duration, 
years 
no. of 
episodes 
Months 
Episodes of 
syncope 
Episodes of 
asystole ≥3 s*  
Months 
Episodes of 
syncope 
Episodes of 
asystole ≥3 s* 
#1 30 20 36 4 3  120 0 np 
#2 12 2 11 0 19  14 0 4 
#3 18 40 24 8 np 24 0 0 
#4 1 2 13 0 27  6 0 0 
#5 3 5 2 1 1 20 0 0 
Median 
(IQR) 
12 (3-18) 5 (2-20) 
13 (11-
24) 
0.11 (0-0.33) 1.11 (0.4-1.8) 20 (14-24) 0 (0-0) 0 (0-0.7) 
#6 2.5 
Frequent 
pre-syncopes 
6 
Frequent 
pre-syncopes 
14 per day (max 
pause 9.2 s) 
1.5 
Frequent 
pre-syncopes 
7 per day  
(max pause 6.7 s) 
* observation with prolonged monitoring by means of implantable loop recorder (ILR) in cases 1-5 and Holter monitoring in 
case 6  
np = not performed; IQR = interquartile range 
 
Wilcoxon matched-pairs signed rank test: too few cases to use this test 
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Table 3. Comparative clinical and laboratory findings in a control group of patients affected by ECG-documented asystolic 
vasovagal/situational syncope  or intrinsic cardiac paroxysmal atrioventricular block  
 
Pat. number 
gender,  
age 
Etiology Clinical features History of 
syncope 
(duration, yrs / 
number of 
episodes) 
ECG 
documentation of 
the index event, 
(longest pause)  
Adenosine 
plasmatic 
level, μmol/L 
(normal range: 
0.40-0.78) 
A2 A adenosine 
receptor 
expression,  AU 
(normal range: 
0.40-0.80) 
Tilt testing 
#1. M, 69 yrs 
Reflex VVS (typical long prodromes) 1 / 5 Brady + Sinus arrest 
(8 s) 
0.90 1.1 positive mixed 
#2. M, 32 yrs 
Reflex VVS (typical long prodromes) Since chiildwood /  
20 
Brady + Sinus arrest 
(16 s) 
1.20 - positive asystole 
#3. F, 71 yrs 
Reflex VVS (typical long prodromes) Since chiildwood /  
1 last year 
Brady + Sinus 
arrest (5 s) 
1.9/1.2 0.98 positive mixed 
#4. F, 68 yrs 
Reflex VVS (typical long prodromes) Since chiildwood / 
7 last year 
Brady + Sinus arrest 
(38 s) 
1.39 1.4/1.5 positive mixed 
#5. M, 44 yrs 
Reflex VVS (typical long prodromes) 5 / 3 Brady + Sinus arrest 
(6.5 s) 
1.67 - negative 
#6. M, 53 yrs 
Reflex VVS (typical long prodromes) 5 / 3 Brady + Sinus arrest 
(3.5 s) 
0.97 - negative 
#7. M, 59 yrs 
Reflex VVS (typical long prodromes) 14 / 8 Brady + Sinus arrest 
(5.5 s) 
1.24 - negative 
#8. F, 83 yrs 
Reflex 
Post-prandial 
4 / 4 
Bradycardia 30 bpm 0.98 - positive asystole 
#9. M, 43 yrs 
Reflex Aypical VVS (atypical short 
prodromes, supine, long 
recovery) 
1 / 5 
Brady + AVB + sinus 
arrest (42 s) 
1.90 - negative 
#10.F, 33 yrs 
Reflex Swallowing syncope 
(reproduced with active 
swallow)  
Since chiildwood / 
>20 
Daily narrow QRS 
AVB  (4 s)  
0.6 0.45 positive mixed 
#11.M, 80 yrs Cardiac Intrinsic AV conduction 
disease 
No Narrow QRS 
paroxysmal AVB 
0.45 - not performed 
#12.F, 79 yrs Cardiac Intrinsic AV conduction 
disease 
0.1/1 Narrow QRS 
paroxysmal AVB 
0.70 - not performed 
#13.F, 79 yrs Cardiac Intrinsic AV conduction 
disease and aortic stenosis 
No Wide QRS 
paroxysmal AVB 
0.45 - not performed 
#13.F, 84 yrs Cardiac Intrinsic AV conduction 
disease and hypertension 
No Narrow QRS 
paroxysmal AVB 
0.35 - not performed 
 
